Furthermore, ADAM17 targeting using genetic, antibody-mediated or pharmacological methods suppresses cell proliferation and tumour growth in cancer models for LAC [29,131], CRC [132], breast cancer [178], prostate cancer [179], pancreatic cancer [180] and ovarian cancer [181]. This evidence concerns the gene ADAM17 and neoplasm.